Filing Analysis
Keros Therapeutics, Inc. announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors as a Class III director, effective July 1, 2026.
📋 Key Facts
- Dr. Anne Prener appointed as Class III Director effective July 1, 2026.
- Term expires at the Company's 2029 annual meeting of stockholders.
- Initial compensation includes a $150,000 stock option grant and a $150,000 RSU award (subject to vesting over 3 years).
- Annual compensation includes an option grant ($75,000), an RSU award ($75,000), and a $41,500 cash retainer.
- Equity grants are subject to ownership caps: initial grants capped at 0.075% of outstanding shares; annual grants capped at 0.0375%.
Keros Therapeutics has voluntarily halted dosing in two treatment arms (3.0 mg/kg and 4.5 mg/kg) of its Phase 2 TROPOS clinical trial for cibotercept (KER-012). The decision follows a safety review triggered by unanticipated pericardial effusion adverse events.
🚩 Red Flags
- Clinical trial safety issue (pericardial effusion)
- Potential delay or termination of the lead drug candidate's development program
- Unanticipated adverse events in a Phase 2 setting
📋 Key Facts
- Trial: TROPOS (Phase 2 clinical trial)
- Drug: cibotercept (KER-012) in combination with background therapy
- Indication: Pulmonary arterial hypertension
- Action: Voluntary dosing halt for the 3.0 mg/kg and 4.5 mg/kg arms
- Reason: Safety review due to unanticipated pericardial effusion adverse events
- Date of event: December 12, 2024
Keros Therapeutics issued an 8-K to announce the release of additional data from its two ongoing Phase 2 clinical trials for elritercept (KER-050). The data was presented at the 66th American Society of Hematology Annual Meeting.
📋 Key Facts
- Company announced Phase 2 clinical trial data for elritercept (KER-050) on December 9, 2024.
- Trials involve patients with myelodysplastic syndromes (MDS) and myelofibrosis.
- Data presentation occurred at the 66th American Society of Hematology Annual Meeting.
Keros Therapeutics entered into a major exclusive license agreement with Takeda Pharmaceuticals for the global development and commercialization of elritercept (KER-050). The deal includes a significant $200 million upfront payment and substantial milestone/royalty potential.
🚩 Red Flags
- Takeda retains the right to terminate the agreement for convenience with notice.
📋 Key Facts
- Entered into an Exclusive License Agreement with Takeda Pharmaceuticals U.S.A., Inc. on December 3, 2024.
- Takeda receives exclusive rights to develop, manufacture, and commercialize elritercept (KER-050) globally (excluding mainland China, Hong Kong, and Macau).
- Upfront payment of $200.0 million due to Keros Therapeutics.
- Potential development/commercial milestones totaling up to $370.0 million.
- Potential sales milestones totaling up to $740.0 million.
- Royalty payments ranging from low double-digits to high teens based on annual net sales.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in two upcoming healthcare conferences: the Piper Sandler Annual Healthcare Conference on December 3, 2024, and the Evercore HealthConx Conference on December 4, 2024.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat at Piper Sandler 36th Annual Healthcare Conference on Dec 3, 2024.
- CEO Jasbir Seehra to participate in a fireside chat at the 7th Annual Evercore HealthConx Conference on Dec 4, 2024.
Keros Therapeutics, Inc. issued an 8-K to furnish its quarterly business highlights and financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing is primarily a placeholder to furnish the press release containing financial results (Item 2.02).
Keros Therapeutics announced that CEO Jasbir Seehra will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 13, 2024.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat presentation.
- Event: Guggenheim Healthcare Innovation Conference.
- Date of event: Wednesday, November 13, 2024, at 3:30 p.m. ET.
Keros Therapeutics announced the appointment of Dr. Yung H. Chyung as Chief Medical Officer, effective November 1, 2024, succeeding Simon Cooper, M.B.B.S.
📋 Key Facts
- Dr. Yung H. Chyung appointed as CMO, effective Nov 1, 2024.
- Succession replaces Simon Cooper, M.B.B.S.
- Annual base salary for Dr. Chyung is $510,000 with a 40% target discretionary bonus.
- Equity incentive includes an option to purchase up to 110,000 shares of common stock.
- Dr. Chyung previously served as EVP and CMO at Tourmaline Bio, Inc. and CMO at Scholar Rock Holding Corporation.
Keros Therapeutics announced the successful completion of patient enrollment for its Phase 2 TROPOS clinical trial. The trial evaluates cibotercept (KER-012) in patients with pulmonary arterial hypertension and exceeded its initial recruitment target.
📋 Key Facts
- Completed enrollment for the TROPOS Phase 2 clinical trial on September 30, 2024.
- Total of 113 patients enrolled, exceeding the original target of 90 patients.
- Trial evaluates cibotercept (KER-012) in combination with background therapy for pulmonary arterial hypertension.
- Topline data readout is expected in the second quarter of 2025.
Keros Therapeutics announced the completion of patient screening for its Phase 2 TROPOS clinical trial evaluating cibotercept (KER-012) for pulmonary arterial hypertension. The company expects to finish enrollment by late September 2024 and release topline data in Q2 2025.
📋 Key Facts
- Completed screening for the Phase 2 TROPOS trial on September 3, 2024.
- Trial evaluates cibotercept (KER-012) in combination with background therapy.
- Indication: Pulmonary arterial hypertension.
- Enrollment is expected to be complete by the end of September 2024.
- Topline data readout is anticipated in the second quarter of 2025.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in several upcoming healthcare conferences including Morgan Stanley, Wells Fargo, and Cantor Global Healthcare. The filing is a routine disclosure of non-material information under Regulation FD.
📋 Key Facts
- CEO Jasbir Seehra to attend Morgan Stanley 22nd Annual Global Healthcare Conference on Sept 4, 2024.
- CEO Jasbir Seehra to attend 2024 Wells Fargo Healthcare Conference on Sept 5, 2024.
- CEO Jasbir Seehra to attend 2024 Cantor Global Healthcare Conference on Sept 19, 2024.
Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. This is a routine disclosure under Regulation FD to ensure all market participants have access to the same information.
📋 Key Facts
- The Company updated its corporate presentation on August 7, 2024.
- The update is intended for use in meetings with investors, analysts, and other parties.
- The presentation was made available via the Company's website as Exhibit 99.1.
Keros Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Results of Operations and Financial Condition).
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 7, 2024.
Keros Therapeutics has filed a prospectus supplement to its existing Shelf Registration Statement to facilitate the issuance and sale of up to $350,000,000 in common stock via an 'at-the-market' (ATM) offering program.
🚩 Red Flags
- Potential for significant shareholder dilution due to the large scale of the $350M offering.
- ATM offerings can create downward pressure on the stock price during execution periods.
📋 Key Facts
- The company is increasing its capacity to sell shares under a Sales Agreement with Leerink Partners LLC.
- Total potential issuance amount: up to $350,000,000 of Common Stock.
- Sales will be conducted via an 'at the market' (ATM) offering on the Nasdaq Global Market.
- Leerink Partners will receive a commission of up to 3.0% of gross sales proceeds.
- The company is not obligated to make any sales under this agreement.
Keros Therapeutics announced a leadership restructuring effective July 1, 2024. CEO Jasbir Seehra will transition to Chair of the Board and step down as President, while Christopher Rovaldi will be promoted to President in addition to his current COO role.
🚩 Red Flags
- None identified; the filing explicitly states Dr. Seehra's resignation from the Presidency was not due to any disagreement with company operations, policies, or practices.
📋 Key Facts
- Jasbir Seehra to resign as President effective June 30, 2024; will become Chair of the Board on July 1, 2024.
- Christopher Rovaldi appointed President and COO effective July 1, 2024.
- Jean-Jacques Bienaimé appointed Lead Independent Director effective July 1, 2024.
- The company amended its Non-Employee Director Compensation Policy to include a $25,000 annual retainer for the Lead Independent Director.
Keros Therapeutics announced the presentation of clinical and preclinical data for its lead candidate, elritercept (KER-050), at the 29th Annual Hybrid Congress of the European Hematology Association. The data covers Phase 2 trials for myelodysplastic syndromes (MDS) and myelofibrosis (MF), alongside positive animal model results.
📋 Key Facts
- Presented Phase 2 clinical trial data for elritercept (KER-050) in MDS and MF patients at the EHA Congress.
- Presented preclinical data showing elritercept promoted erythropoiesis and mitigated anemia in an animal model of MF.
- Preclinical results indicated improved anemia associated with ruxolitinib therapy and improved muscle mass/function in animal models.
- The company held a conference call on June 17, 2024, to discuss pipeline updates.
Keros Therapeutics announced positive FDA feedback regarding the design and endpoints for its Phase 3 clinical trial of KER-050 in MDS patients. The company also provided updates on its Phase 2 enrollment timeline for KER-012.
📋 Key Facts
- FDA expressed general alignment on the design and endpoints for a proposed pivotal Phase 3 clinical trial for KER-050 (elritercept) in myelodysplastic syndromes (MDS).
- Phase 2 enrollment for KER-012 (cibotercept) in pulmonary arterial hypertension is expected to complete in Q4 2024.
- Company scheduled a corporate update conference call/webcast for June 17, 2024.
Keros Therapeutics announced that its President and CEO, Jasbir Seehra, will participate in a fireside chat at the Goldman Sachs 45th Annual Healthcare Conference on June 10, 2024.
📋 Key Facts
- CEO Jasbir Seehra to present at the Goldman Sachs 45th Annual Healthcare Conference.
- Presentation scheduled for Monday, June 10, 2024, at 2:40 p.m. ET.
- The filing is a Regulation FD disclosure regarding non-public information being shared via a public presentation.
Keros Therapeutics held its 2024 Annual Meeting of Stockholders on May 30, 2024. The meeting resulted in the election of three directors and the approval of several advisory proposals regarding auditor ratification and executive compensation.
📋 Key Facts
- Annual Meeting held on May 30, 2024.
- Three nominees elected to the Board: Jasbir Seehra, Ph.D., Nima Farzan, and Julius Knowles, serving until the 2027 Annual Meeting.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2024 (Proposal 2).
- Stockholders approved executive compensation on a non-binding advisory basis (Proposal 3).
- Stockholders voted in favor of an annual frequency for shareholder advisory votes on executive compensation (Proposal 4).
Keros Therapeutics, Inc. announced the appointment of Jean-Jacques Bienaimé to its Board of Directors and the Nominating Committee, effective June 1, 2024.
📋 Key Facts
- Jean-Jacques Bienaimé appointed as Class III director, term expiring at the 2026 annual meeting.
- Effective date of appointment: June 1, 2024.
- Appointed to serve on the Nominating and Corporate Governance Committee.
- Compensation includes an initial stock option grant for 20,000 shares vesting over three years.
- Annual compensation includes a $40,000 cash retainer and a $5,000 committee retainer.
- Eligible for annual grants of 10,000 shares per year.
Keros Therapeutics, Inc. issued an 8-K to furnish its quarterly business highlights and financial results for the period ending March 31, 2024.
📋 Key Facts
- The filing is a routine disclosure of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Date of report: May 8, 2024.
Keros Therapeutics announced that the FDA has granted Fast Track designation for its drug candidate KER-050 (elritercept) to treat anemia in patients with myelodysplastic syndromes. This regulatory milestone is intended to expedite the development and review process of the therapeutic.
📋 Key Facts
- FDA granted Fast Track designation for KER-050 (elritercept).
- Target indication: Anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes.
- Filing date: March 14, 2024.
Keros Therapeutics updated its corporate presentation to be used in meetings with investors and analysts. This is a routine regulatory filing under Regulation FD.
📋 Key Facts
- The company updated its corporate presentation on March 6, 2024.
- The update is intended for use in meetings with investors, analysts, and other stakeholders.
- The presentation is available via the Company's website and attached as Exhibit 99.1.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on March 12, 2024. This is a routine regulatory disclosure under Item 7.01 regarding Regulation FD.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference.
- Event date: Tuesday, March 12, 2024, at 3:00 p.m. ET.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Keros Therapeutics announced the voluntary resignation of its Chief Medical Officer, Simon Cooper, effective March 12, 2024. The company has initiated a search for a successor.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a clinical-stage biotech company can disrupt clinical development timelines or strategy.
📋 Key Facts
- Simon Cooper, M.B.B.S., resigned as Chief Medical Officer on February 29, 2024.
- The resignation is effective March 12, 2024.
- The departure is voluntary and not due to any disagreement with the Company.
- The Company has commenced a search for a new CMO.
Keros Therapeutics issued an 8-K to furnish its quarterly and annual business highlights and financial results for the period ended December 31, 2023. The filing serves as a formal announcement of their recent operational performance.
📋 Key Facts
- Reporting period: Quarter and year ended December 31, 2023.
- Filing date: February 28, 2024.
- The company issued a press release (Exhibit 99.1) containing business highlights and financial results.
Keros Therapeutics announced the closing of an underwritten public offering of common stock. The company successfully raised significant capital, significantly extending its cash runway into 2027.
📋 Key Facts
- Closed underwritten public offering of 4,025,000 shares at $40.00 per share on January 8, 2024.
- Underwriters fully exercised their option to purchase an additional 525,000 shares.
- Net proceeds from the Offering (before expenses) were approximately $151.3 million.
- Combined with existing cash and previous ATM sales ($68.5M), the company expects to fund operations into 2027.
Keros Therapeutics entered into an underwriting agreement to offer 3.5 million shares of common stock at $40.00 per share. The company expects to net approximately $131.2 million to fund clinical trials and R&D activities.
🚩 Red Flags
- Equity dilution: Issuance of 3.5 million new shares will dilute existing shareholders.
📋 Key Facts
- Offering size: 3,500,000 shares of common stock.
- Offering price: $40.00 per share.
- Estimated net proceeds: Approximately $131.2 million.
- Underwriters include Goldman Sachs & Co. LLC, Leerink Partners LLC, Piper Sandler & Co., and Truist Securities, Inc.
- Expected closing date: January 8, 2024.
- Use of proceeds includes advancing KER-050 (Phase 2/3), KER-012 (Phase 2), and KER-065 (Phase 1) clinical programs.
Keros Therapeutics updated its corporate presentation and announced the commencement of a Phase 1 clinical trial for KER-065, a novel ligand trap targeting obesity.
📋 Key Facts
- Updated corporate presentation released on January 3, 2024 (Exhibit 99.1).
- Announced development of KER-065, a ligand trap designed to inhibit TGF-ß ligands (including myostatin/GDF8 and activin A) for obesity treatment.
- Commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial evaluating single and multiple ascending doses of KER-065 in healthy volunteers.